98%
921
2 minutes
20
Non-invasive ventilation (NIV) plays a critical role in the management of acute and chronic respiratory failure, offering benefits over invasive mechanical ventilation. However, its use is associated with various adverse events that may impact clinical outcomes. This systematic review aimed to evaluate the types, frequencies, and clinical consequences of complications related to NIV. A systematic search of PubMed, EMBASE, and Cochrane Library databases was conducted according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses 'PRISMA' guidelines, covering studies published between 2000 and February 2023. Eligible studies included randomized controlled trials, observational cohorts, and systematic reviews reporting adverse events in adults receiving NIV for respiratory failure. Thirty-two studies involving approximately 6,000 patients were analyzed. NIV-related complications were frequently reported, including, physiological (e.g., hypercapnia 2-10%, hypoxemia 1-5%), mechanical (e.g., skin breakdown 5-15%, air leaks 5-25%), and patient-related events (e.g., discomfort 10-30%, anxiety 5-15%). Face masks were linked to higher rates of air leaks and intolerance, while helmet interfaces showed fewer complications. Helmet interfaces and newer ventilator technologies showed advantages in minimizing certain adverse events. Although NIV offers substantial benefits compared to invasive ventilation, its effectiveness can be compromised by preventable complications. Structured monitoring, early intervention, and a multidisciplinary care approach are essential for maximizing outcomes. Further research is needed to develop strategies that enhance patient comfort, minimize complications, and optimize NIV application across different clinical settings.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.4274/ThoracResPract.2025.2025-4-8 | DOI Listing |
Br J Haematol
September 2025
Department of Hematology, The First Affiliated Hospital of University of Science and Technology of China, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
Refractory cytomegalovirus (CMV) infection is a severe complication following umbilical cord blood transplantation (UCBT). Antiviral agents, the standard first-line therapy, are limited by toxicity and resistance without robust T-cell immunity. We evaluated third-party donor (TPD)-derived CMV-specific T cells (CMVSTs) as a treatment option.
View Article and Find Full Text PDFJ Dermatolog Treat
December 2025
Department of Dermatology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
Background: Bullous pemphigoid (BP) is a common autoimmune subepidermal bullous disease. Dupilumab, an IL-4/IL-13 inhibitor, represents a novel therapeutic approach for BP, but real-world long-term data in super-elderly patients are limited.
Methods: This retrospective, single-center observational study included super-elderly BP patients (≥80 years) receiving dupilumab monotherapy from September 2022 to September 2024.
Infect Dis Ther
September 2025
School of Biomedical Sciences, The Chinese University of Hong Kong (CUHK), Hong Kong SAR, China.
Introduction: The high mortality of Coronavirus Disease 2019 (COVID-19) highlights the need for safe and effective antiviral treatment. Small molecular antivirals (remdesivir, molnupiravir, nirmatrelvir/ritonavir) and immunomodulators (baricitinib, tocilizumab) have been developed or repurposed to suppress viral replication and ameliorate cytokine storms, respectively. Despite U.
View Article and Find Full Text PDFAesthetic Plast Surg
September 2025
Department of Plastic Surgery, The First Affiliated Hospital, Jinan University, No. 613 West, Huangpu Avenue, Guangzhou, 510630, Guangdong Province, China.
Background: Microfocused ultrasound (MFU) is a non-invasive technique used for facial rejuvenation, yet there is limited quantitative data on its long-term effects. This study aimed to evaluate the long-term efficacy and safety of MFU for facial rejuvenation. We utilized standardized photography along with advanced skin assessment technologies to analyze the impact of MFU on facial morphology, skin function, and patient satisfaction over a 12-month period.
View Article and Find Full Text PDFCancer Immunol Immunother
September 2025
Department of Gastric Surgery, Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Hangzhou, 310022, Zhejiang, China.
Objectives: To evaluate the efficacy of combining PD-1 inhibitors with chemotherapy in conversion therapy for patients with stage IV gastric cancer and to determine the populations most likely to benefit from this regimen.
Methods: Data from patients with stage IV gastric cancer who received conversion therapy with PD-1 inhibitors combined with chemotherapy between January 2018 and December 2022 at multiple centers were retrospectively reviewed. Patients who underwent conversion surgery were categorized into a surgery group, while those who did not were placed into a palliative group.